文献速递胸部肿瘤

循环肿瘤DNA检测局部肺癌分子残留病灶的早期发现

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.
PubMed 文献 · Cancer Discov · 2017-09-24

该研究对40例接受根治性治疗的I-III期肺癌患者及54名健康成人的255份样本进行CAPP-seq ctDNA分析,发现94%的可评估复发患者首次治疗后血样中可检出ctDNA,且ctDNA检出中位提前5.2个月于影像学进展,部分患者携带与TKI或免疫检查点抑制剂 favorable 反应相关的突变谱。

要点

  • 94%可评估复发患者首次治疗后血样中可检出ctDNA,提示MRD可靠识别。
  • 72%患者ctDNA检出中位提前5.2个月于影像学进展。
  • 53%患者ctDNA突变谱与TKI或免疫检查点抑制剂 favorable 反应相关。

核心结论

  • CAPP-seq可准确检测肺癌患者ctDNA MRD,并可能允许在疾病负荷最低时进行个性化辅助治疗。

研究设计与样本

  • 研究对40例接受根治性治疗的I-III期肺癌患者及54名健康成人的255份样本进行CAPP-seq ctDNA分析。

主要发现

  • 94%的可评估复发患者首次治疗后血样中可检出ctDNA。
  • 72%患者ctDNA检出中位提前5.2个月于影像学进展。
  • 53%患者携带与TKI或免疫检查点抑制剂 favorable 反应相关的ctDNA突变谱。

关键数值与推荐

  • 94%可评估复发患者首次治疗后血样中可检出ctDNA。
  • 72%患者ctDNA检出中位提前5.2个月于影像学进展。
  • 53%患者ctDNA突变谱与TKI或免疫检查点抑制剂 favorable 反应相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization of adjuvant therapies. Here, we apply cancer personalized profiling by deep sequencing (CAPP-seq) circulating tumor DNA (ctDNA) analysis to 255 samples from 40 patients treated with curative intent for stage I-III lung cancer and 54 healthy adults. In 94% of evaluable patients experiencing recurrence, ctDNA was detectable in the first posttreatment blood sample, indicating reliable identification of MRD. Posttreatment ctDNA detection preceded radiographic progression in 72% of patients by a median of 5.2 months, and 53% of patients harbored ctDNA mutation profiles associated with favorable responses to tyrosine kinase inhibitors or immune checkpoint blockade. Collectively, these results indicate that ctDNA MRD in patients with lung cancer can be accurately detected using CAPP-seq and may allow personalized adjuvant treatment while disease burden is lowest.Significance: This study shows that ctDNA analysis can robustly identify posttreatment MRD in patients with localized lung cancer, identifying residual/recurrent disease earlier than standard-of-care radiologic imaging, and thus could facilitate personalized adjuvant treatment at early time points when disease burden is lowest. Cancer Discov; 7(12); 1394-403. ©2017 AACR.See related commentary by Comino-Mendez and Turner, p. 1368This article is highlighted in the In This Issue feature, p. 1355.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017. PMID: 28899864. doi:10.1158/2159-8290.CD-17-0716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。